Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Current Leases (2023 - 2026)

ArriVent BioPharma has reported Current Leases over the past 4 years, most recently at $99000.0 for Q1 2026.

  • Quarterly results put Current Leases at $99000.0 for Q1 2026, down 28.26% from a year ago — trailing twelve months through Mar 2026 was $99000.0 (down 28.26% YoY), and the annual figure for FY2025 was $14000.0, down 91.36%.
  • Current Leases reached $99000.0 in Q1 2026 per AVBP's latest filing, up from $14000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $162000.0 in Q4 2024 and bottomed at $14000.0 in Q4 2025.
  • Median Current Leases over the past 4 years was $139000.0 (2023), compared with a mean of $116300.0.
  • The largest annual shift saw Current Leases rose 15.71% in 2024 before it crashed 91.36% in 2025.
  • Over 4 years, Current Leases stood at $140000.0 in 2023, then rose by 15.71% to $162000.0 in 2024, then plummeted by 91.36% to $14000.0 in 2025, then soared by 607.14% to $99000.0 in 2026.
  • Business Quant data shows Current Leases for AVBP at $99000.0 in Q1 2026, $14000.0 in Q4 2025, and $56000.0 in Q3 2025.